[go: up one dir, main page]

WO2025006988A3 - Galectin-3-targeted and p-selectin-targeted nanotherapies - Google Patents

Galectin-3-targeted and p-selectin-targeted nanotherapies Download PDF

Info

Publication number
WO2025006988A3
WO2025006988A3 PCT/US2024/036162 US2024036162W WO2025006988A3 WO 2025006988 A3 WO2025006988 A3 WO 2025006988A3 US 2024036162 W US2024036162 W US 2024036162W WO 2025006988 A3 WO2025006988 A3 WO 2025006988A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted
selectin
galectin
nanotherapies
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/036162
Other languages
French (fr)
Other versions
WO2025006988A2 (en
Inventor
Daniel Alan Heller
Magdalini PANAGIOTAKOPOULOS
Emma GRABARNIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2025006988A2 publication Critical patent/WO2025006988A2/en
Publication of WO2025006988A3 publication Critical patent/WO2025006988A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present technology relates generally to lipid nanoparticles including a therapeutic agent and a sulfolipid targeting P-selectin or a ganglioside targeting Galectin-3 for treating or preventing a disease in a subject.
PCT/US2024/036162 2023-06-30 2024-06-28 Galectin-3-targeted and p-selectin-targeted nanotherapies Pending WO2025006988A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363511568P 2023-06-30 2023-06-30
US63/511,568 2023-06-30
US202363595955P 2023-11-03 2023-11-03
US63/595,955 2023-11-03

Publications (2)

Publication Number Publication Date
WO2025006988A2 WO2025006988A2 (en) 2025-01-02
WO2025006988A3 true WO2025006988A3 (en) 2025-04-17

Family

ID=93940042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/036162 Pending WO2025006988A2 (en) 2023-06-30 2024-06-28 Galectin-3-targeted and p-selectin-targeted nanotherapies

Country Status (1)

Country Link
WO (1) WO2025006988A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237109A1 (en) * 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
WO2019073371A1 (en) * 2017-10-11 2019-04-18 Wockhardt Limited Pharmaceutical composition comprising albumin-lipid hybrid nanoparticles
WO2020262150A1 (en) * 2019-06-24 2020-12-30 国立大学法人北海道大学 Lipid nanoparticle
WO2021155274A1 (en) * 2020-01-31 2021-08-05 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2021257586A1 (en) * 2020-06-17 2021-12-23 Disruption Labs Inc. Compositions for supplementing products with therapeutic agents and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237109A1 (en) * 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
WO2019073371A1 (en) * 2017-10-11 2019-04-18 Wockhardt Limited Pharmaceutical composition comprising albumin-lipid hybrid nanoparticles
WO2020262150A1 (en) * 2019-06-24 2020-12-30 国立大学法人北海道大学 Lipid nanoparticle
WO2021155274A1 (en) * 2020-01-31 2021-08-05 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2021257586A1 (en) * 2020-06-17 2021-12-23 Disruption Labs Inc. Compositions for supplementing products with therapeutic agents and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOTYŃSKA JOANNA, FIGASZEWSKI ZBIGNIEW A.: "Microelectrophoretic investigation of the interactions between liposomal membranes formed from a phosphatidylcholine-phosphatidylglycerol mixture and monovalent ions", THE EUROPEAN PHYSICAL JOURNAL E, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 37, no. 10, 1 October 2014 (2014-10-01), Berlin/Heidelberg, pages 92 - 92-6, XP093305902, ISSN: 1292-8941, DOI: 10.1140/epje/i2014-14092-3 *
LIN JIA, SHIGDAR SARAH, FANG DING ZHI, XIANG DOGNXI, WEI MING Q., DANKS ANDREW, KONG LINGXUE, LI LIANGHONG, QIAO LIANG, DUAN WEI: "Improved Efficacy and Reduced Toxicity of Doxorubicin Encapsulated in Sulfatide-Containing Nanoliposome in a Glioma Model", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 9, no. 7, US , pages e103736, XP093305907, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0103736 *
PATRA MALAY; MANDAL MANOJ; CHAKRABARTI ABHIJIT; MUKHOPADHYAY CHAITALI: "Localization and dynamics of the anticarcinogenic curcumin with GM1and other miceller assemblies", GLYCOCONJUGATE JOURNAL, CHAPMAN & HALL, BOSTON, vol. 34, no. 2, 19 November 2016 (2016-11-19), Boston , pages 171 - 179, XP036177270, ISSN: 0282-0080, DOI: 10.1007/s10719-016-9748-1 *

Also Published As

Publication number Publication date
WO2025006988A2 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
Phillips Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories
ES2254960T3 (en) COMBINATION OF BETA-2 ADRENORRECEPTOR AGONISTS AND AMINOAZUCARES AND ITS USE FOR THE TREATMENT OF IMMUNOMODULAR DISORDERS.
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2012012300A3 (en) Treatment of the adverse side-effects associated with administration of an anti-hyaluronan agent
RU2002124589A (en) DRUG FOR REDUCING AND / OR BLOCKING ADHESION OF PATHOGENIC SUBSTANCES AND ORGANISMS, APPLICATION OF ANTI-ADHESIVE CARBOHYDRATES
JP2007501286A (en) Ready-to-use devices containing preformed hydrogel products
WO2008076579A3 (en) Method of controlling body weight in estrogen-insufficient women
CA2122519A1 (en) Cancer Treatment and Metastasis Prevention
WO2007095056A3 (en) Slow intraventricular delivery
JP2017025078A (en) Skin external composition comprising salt and sugar as active ingredients for preventing and treating vaginosis and use thereof
US20080182816A1 (en) Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
EP3316856B1 (en) Blended formulations
WO2025006988A3 (en) Galectin-3-targeted and p-selectin-targeted nanotherapies
Bhatt et al. The impact of carrageenan on pharmascience
JP2019116441A5 (en)
Herzner et al. Spacer-separated sialyl LewisX cyclopeptide conjugates as potential E-selectin ligands
CN103191408A (en) Medicine composition and gel for treating colpitis and applications thereof
RU2003113129A (en) METHOD FOR PREVENTION OF INNEROBIC INFECTIONS IN CHILDREN
WO2023107712A8 (en) SOLUBLE β-GLUCANS FOR INDUCING TRAINED IMMUNITY
EP3129031B1 (en) Composition for treating stomach pain
NO20022288L (en) Composition for the prevention and / or treatment of disorders caused by abnormal lipid metabolism, including propionyl L-carnitine and chitosan
US20050070500A1 (en) Method of modulating release of saccharides and uses thereof
CN109010353A (en) A kind of biological polyoses material compositions for treating chemicotherapy patient's oral mucosa ulcer
US8778892B2 (en) Compounds and methods for treatment of solid tumors
CN206909097U (en) A kind of wheeled tractor paddy field rut covering device